NCT03380793View on ClinicalTrials.gov

A Trial to Assess the Efficacy and Safety of Morinidazole in Patients With Appendicitis

PHASE4UnknownINTERVENTIONAL
Enrollment

614

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

October 31, 2018

Study Completion Date

October 31, 2018

Conditions
Appendicitis
Interventions
DRUG

morinidazole

morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 5-7 days) with aztreonam and (or) etimicin.

Trial Locations (1)

100853

RECRUITING

PLA General Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY

NCT03380793 - A Trial to Assess the Efficacy and Safety of Morinidazole in Patients With Appendicitis | Biotech Hunter | Biotech Hunter